HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yann Bergé Selected Research

imgatuzumab

2/2014Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
10/2011Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yann Bergé Research Topics

Disease

2Breast Neoplasms (Breast Cancer)
01/2013 - 06/2011
1Febrile Neutropenia
01/2018
1Colorectal Neoplasms (Colorectal Cancer)
02/2014
1Neoplasms (Cancer)
10/2011
1Head and Neck Neoplasms (Head and Neck Cancer)
06/2011

Drug/Important Bio-Agent (IBA)

2imgatuzumabIBA
02/2014 - 10/2011
1Vinorelbine (Navelbine)FDA LinkGeneric
01/2018
1AfatinibIBA
01/2018
1Estrogens (Estrogen)FDA Link
01/2013
1Estrogen ReceptorsIBA
01/2013
1ErbB Receptors (EGF Receptor)IBA
10/2011
1Monoclonal AntibodiesIBA
10/2011
1Eukaryotic Initiation Factor-4EIBA
06/2011
1Eukaryotic Initiation Factor-4F (EIF4F)IBA
06/2011
1Cetuximab (Erbitux)FDA Link
06/2011
1Trastuzumab (Herceptin)FDA Link
06/2011
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2011